cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.17427508
title: A Silurian-Devonian active margin in the proto-Andes – new data on an old conundrum

description: The Devonian Terra Australis accretionary orogen along the proto-Andes is characterized south of 33°S by the eastward accretion of the Chilenia and Chaitenia terranes. From the middle Silurian to the early Carboniferous the evolution north of 33°S, in the southern central Andes, is enigmatic, and herein called the Silurian-Devonian lull. This lull is notable for the absence of magmatism, metamorphism and deformation while mature siliciclastic detritus accumulated in marginal basins governed by depositional and not by tectonic controls. Detrital zircon age spectra uniformly display a marked scarcity of Silurian and Devonian ages. No evidence of a Devonian active margin system has been put forward so far. Newly discovered volcanic arc lavas in the Devonian-early Carboniferous Compléjo Epimetamórfico Chañaral (CEMC) of northern Chile give evidence of Devonian to early Carboniferous intermediate arc magmatism in this area for the first time. The CEMC also includes mafic volcanic rocks as syndepositional intercalations and as tectonic accretions. They predominantly have E-MORB and OIB characteristics and very likely formed at an extensional volcanic rifted margin environment. The veiled presence of scarce arc magmatism during the Silurian-Devonian lull might be taken as evidence of flat-slab subduction. However, present-day flat-slab regimes produce strongly telescoped mountain belts with high topography and relief. The absence of any deformation during the lull attests against this interpretation. Assuming an extension of Chilenia into northern Chile is unlikely because of different stratigraphies and the absence of ophiolitic sutures. The Silurian-Devonian lull may be explained as a magmatic lull between the flare-ups of the Famatinian and Gondwanide orogenies (Cambrian-Ordovician and Carboniferous-Triassic, respectively) the latter of which is attributed to rapid trenchward migration of the volcanic axis. Magmatic lulls are characterized by less than 25% of magma production relative to flare-ups and occur at times of slow landward migration of an arc system.
DOI: 10.48370/ofd/vwqoiz/ol4iy3
title: HMW_Vicia_sepium_L._H_5908.jpg

description: :unav
DOI: 10.48370/ofd/vwqoiz
title: Wyka płotowa (Vicia sepium L.), 5908

description: Herbarium
DOI: 10.48370/ofd/0lvzsj/jpfikx
title: HMW_Vicia_sepium_L._H_0785.jpg

description: :unav
DOI: 10.48370/ofd/0lvzsj
title: Wyka płotowa (Vicia sepium L.), 785

description: Herbarium
DOI: 10.6084/m9.figshare.17427509
title: Supplementary Material for: Effects of Sodium-Glucose Cotransporter 2 on Amputation Events: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials

description: <b><i>Introduction:</i></b> Sodium-glucose cotransporter 2 (SGLT2) inhibitors are increasingly utilized in the treatment of diabetes mellitus as well as therapeutic extra-glycemic effects. However, there are still concerns over complications such as amputation events, given the results from the Canagliflozin Cardiovascular Assessment Study (CANVAS) trial. Hence, we conducted a systematic review and meta-analysis of randomized-controlled trials to investigate the effect of SGLT2 inhibitors on amputation events. <b><i>Methods:</i></b> Four electronic databases (PubMed, Embase, Cochrane, and SCOPUS) were searched on November 21, 2020, for articles published from January 1, 2000, up to November 21, 2020, for studies that examined the effect of SGLT2 inhibitors on amputation events. Random-effect pair-wise meta-analysis for hazard ratios and fixed-effect Peto odds ratio meta-analysis were utilized to summarize the studies. <b><i>Results:</i></b> A total of 15 randomized-controlled trials were included with a combined cohort of 63,716 patients. We demonstrated that there was no significant difference in amputation events across different types of SGLT2 inhibitors, different baseline populations, and different duration of SGLT2 inhibitor use. <b><i>Discussion/Conclusions:</i></b> In this meta-analysis, SGLT2 inhibitors were not associated with a significant difference in amputation events.
DOI: 10.48370/ofd/nxywac/jx6ewx
title: HMW_Vicia_sativa_L._H_9101.jpg

description: :unav
DOI: 10.48370/ofd/nxywac
title: Wyka siewna (Vicia sativa L.), 9101

description: Herbarium
DOI: 10.48370/ofd/psglfn/9dnx7n
title: HMW_Vicia_sativa_L._H_4806.jpg

description: :unav
DOI: 10.48370/ofd/psglfn
title: Wyka siewna (Vicia sativa L.), 4806

description: Herbarium
DOI: 10.48370/ofd/vjnzsq/nbibpc
title: HMW_Vicia_pisiformis_L._H_8585.jpg

description: :unav
DOI: 10.48370/ofd/vjnzsq
title: Wyka grochowata (Vicia pisiformis L.), 8585

description: Herbarium
DOI: 10.48370/ofd/auxri6/ugrg9k
title: HMW_Vicia_pisiformis_L._H_8570.jpg

description: :unav
DOI: 10.48370/ofd/auxri6
title: Wyka grochowata (Vicia pisiformis L.), 8570

description: Herbarium
DOI: 10.6084/m9.figshare.17012198
title: Supplementary Material for: Surveillance of liver function in uveitis with or without chronic HBV infection

description: Introduction: Immunosuppressive therapy for uveitis may cause liver damage. Methods: To investigate incidence of liver damage during uveitis treatment, we compared serological Hepatitis B core antibody (HBcAb) status with risk of liver dysfunction in all participants (n=992), in anterior uveitis (AU) (n=489) and combined of intermediate, posterior or panuveitis patients (IPPU) (n=503). The primary endpoint was incidence of elevated serum ALT level above two-fold upper limits of normal (ULN) within 6 months. Results: The incidence rate of primary endpoint for HBcAb negative and positive patients was 65 and 212 per 1,000 person years, respectively. The absolute rate difference was 147 (95% CI, 80-213) per 1,000 person years. HBcAb positivity was associated with a higher risk for primary endpoint in all participants (aHR, 3.53; 95% CI, 1.79-6.99; P value = 2.8×10-4) and in IPPU (aHR, 3.80; 95% CI, 1.61-9.01; P value = 0.002). No significant association with primary endpoint was observed for HBcAb positivity in AU (aHR, 3.21; 95% CI, 0.94-10.95; P value = 0.063). AU was mainly treated with topical eye drops (74.0%) whereas IPPU cases received systemic therapy including prednisone (94.0%), cyclosporine (80.9%) or other additionally combined immunomodulatory agents (14.9%). Conclusion: Non-infectious uveitis cases with HBcAb positivity have an increased risk of liver damage. This association was predominantly driven by IPPU but was not significant in AU suggesting that the association is mediated by systemic therapy.
DOI: 10.6084/m9.figshare.17427526
title: SA1 from Biophysical models of dispersal contribute to seascape genetic analyses

description: Data matrix on details of the 103 assessments.
DOI: 10.6084/m9.figshare.17427526.v1
title: SA1 from Biophysical models of dispersal contribute to seascape genetic analyses

description: Data matrix on details of the 103 assessments.
DOI: 10.5517/ccdc.csd.cc1kfpvj
title: CCDC 1443138: Experimental Crystal Structure Determination

description: Related Article: Ji-Bin Zhuo, Ji-Cheng Wang, Yao-Feng Yuan|2021|J.Organomet.Chem.|959|122185|doi:10.1016/j.jorganchem.2021.122185
DOI: 10.5517/ccdc.csd.cc1kj7v5
title: CCDC 1445587: Experimental Crystal Structure Determination

description: Related Article: Ji-Bin Zhuo, Ji-Cheng Wang, Yao-Feng Yuan|2021|J.Organomet.Chem.|959|122185|doi:10.1016/j.jorganchem.2021.122185
DOI: 10.5517/ccdc.csd.cc2246fw
title: CCDC 1910667: Experimental Crystal Structure Determination

description: Related Article: Reece D. Crocker, Domenic P. Pace, Bolong Zhang, Demelza J. M. Lyons, Mohan M. Bhadbhade, Wallace W. H. Wong, Binh Khanh Mai, Thanh Vinh Nguyen|2021|J.Am.Chem.Soc.|143|20384|doi:10.1021/jacs.1c10038
description: Related Article: Reece Crocker, Vinh Nguyen|2019|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc23kbrs
title: CCDC 1953085: Experimental Crystal Structure Determination

description: Related Article: Reece D. Crocker, Domenic P. Pace, Bolong Zhang, Demelza J. M. Lyons, Mohan M. Bhadbhade, Wallace W. H. Wong, Binh Khanh Mai, Thanh Vinh Nguyen|2021|J.Am.Chem.Soc.|143|20384|doi:10.1021/jacs.1c10038
description: Related Article: Reece Crocker|2019|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc26rxkg
title: CCDC 2048776: Experimental Crystal Structure Determination

description: Related Article: Andrii Malashchuk, Anton V. Chernykh, Mariana Y. Perebyinis, Igor V. Komarov, Oleksandr O. Grygorenko|2021|Eur.J.Org.Chem.|2021|6570|doi:10.1002/ejoc.202001614
DOI: 10.5517/ccdc.csd.cc26rxlh
title: CCDC 2048777: Experimental Crystal Structure Determination

description: Related Article: Andrii Malashchuk, Anton V. Chernykh, Mariana Y. Perebyinis, Igor V. Komarov, Oleksandr O. Grygorenko|2021|Eur.J.Org.Chem.|2021|6570|doi:10.1002/ejoc.202001614
DOI: 10.5517/ccdc.csd.cc26rxmj
title: CCDC 2048778: Experimental Crystal Structure Determination

description: Related Article: Andrii Malashchuk, Anton V. Chernykh, Mariana Y. Perebyinis, Igor V. Komarov, Oleksandr O. Grygorenko|2021|Eur.J.Org.Chem.|2021|6570|doi:10.1002/ejoc.202001614
DOI: 10.5517/ccdc.csd.cc277b4z
title: CCDC 2062620: Experimental Crystal Structure Determination

description: Related Article: Mohcine Missioui, Musa A. Said, Güneş Demirtaş, Joel T. Mague, Ahlam Al-Sulami, Nadia S. Al-Kaff, Youssef Ramli|2021|Arab.J.Chem.|15|103595|doi:10.1016/j.arabjc.2021.103595
DOI: 10.5517/ccdc.csd.cc27xh8y
title: CCDC 2082960: Experimental Crystal Structure Determination

description: Related Article: Hong-yan Mu, Chen-yuan Gong, Ru-jun Zhang, Zhen-hua Chen, Shi-guo Zhu, Wei-min Zhao|2021|Bioorg.Chem.|119|105534|doi:10.1016/j.bioorg.2021.105534
DOI: 10.48370/ofd/ioymg9/7gfktb
title: HMW_Vicia_lathyroides_L._H_7189.jpg

description: :unav
DOI: 10.48370/ofd/ioymg9
title: Wyka lędźwianowata (Vicia lathyroides L.), 7189

description: Herbarium
DOI: 10.48370/ofd/1igeek/vdomzs
title: HMW_Vicia_lathyroides_L._H_7188.jpg

description: :unav
DOI: 10.48370/ofd/1igeek
title: Wyka lędźwianowata (Vicia lathyroides L.), 7188

description: Herbarium
DOI: 10.5519/qd.dkmem6e9
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (9520 records)
DOI: 10.48370/ofd/d0geah/ecbmsa
title: HMW_Vicia_hirsuta_(L.)_Gray_H_2379.jpg

description: :unav
DOI: 10.48370/ofd/d0geah
title: Wyka drobnokwiatowa (Vicia hirsuta (L.) Gray), 2379

description: Herbarium
DOI: 10.48370/ofd/qr5jo7/qwkmn3
title: HMW_Vicia_hirsuta_(L.)_Gray_H_2317.jpg

description: :unav
DOI: 10.48370/ofd/qr5jo7
title: Wyka drobnokwiatowa (Vicia hirsuta (L.) Gray), 2317

description: Herbarium
DOI: 10.48370/ofd/kkf4fi/yulspe
title: HMW_Vicia_hirsuta_(L.)_Gray_H_0812.jpg

description: :unav
DOI: 10.48370/ofd/kkf4fi
title: Wyka drobnokwiatowa (Vicia hirsuta (L.) Gray), 812

description: Herbarium
DOI: 10.48370/ofd/1gsf7j/djzuyd
title: HMW_Vicia_hirsuta_(L.)_Gray_H_2315.jpg

description: :unav
DOI: 10.48370/ofd/1gsf7j
title: Wyka drobnokwiatowa (Vicia hirsuta (L.) Gray), 2315

description: Herbarium
DOI: 10.48370/ofd/5h37ra/midqw3
title: HMW_Vicia_grandiflora_Scop._H_7194.jpg

description: :unav
DOI: 10.48370/ofd/5h37ra
title: Wyka brudnożółta (Vicia grandiflora Scop.), 7194

description: Herbarium
DOI: 10.48370/ofd/mv9evu/uf2w9o
title: HMW_Vicia_grandiflora_Scop._H_8004.jpg

description: :unav
DOI: 10.48370/ofd/mv9evu
title: Wyka brudnożółta (Vicia grandiflora Scop.), 8004

description: Herbarium
DOI: 10.48370/ofd/p9dtxh/mzbyag
title: HMW_Vicia_grandiflora_Scop._H_8284.jpg

description: :unav
DOI: 10.48370/ofd/p9dtxh
title: Wyka brudnożółta (Vicia grandiflora Scop.), 8284

description: Herbarium
DOI: 10.6084/m9.figshare.17427577
title: Treadmill Running Raw Data from Sprinting with prosthetic versus biological legs: insight from experimental data

description: Treadmill ground reaction force data from the fastest athlete with bilateral leg amputations at 3 to 11.4 m/s
DOI: 10.6084/m9.figshare.17427577.v1
title: Treadmill Running Raw Data from Sprinting with prosthetic versus biological legs: insight from experimental data

description: Treadmill ground reaction force data from the fastest athlete with bilateral leg amputations at 3 to 11.4 m/s
DOI: 10.6084/m9.figshare.17427572.v1
title: data of raw microplastic observations from Figure S1 of Van Sebille et al (2015, ERL) paper

description: Data files of the data of microplastic raw (i.e. non-standardised) microplastic observations from Figure S1 of the Van Sebille et al (2015, Environmental Research Letters, doi:10.1088/1748-9326/10/12/124006) paper<br>
DOI: 10.6084/m9.figshare.17427572
title: data of raw microplastic observations from Figure S1 of Van Sebille et al (2015, ERL) paper

description: Data files of the data of microplastic raw (i.e. non-standardised) microplastic observations from Figure S1 of the Van Sebille et al (2015, Environmental Research Letters, doi:10.1088/1748-9326/10/12/124006) paper<br>
DOI: 10.6084/m9.figshare.17427586.v1
title: Running Performance Metric Summary Data from Sprinting with prosthetic versus biological legs: insight from experimental data

description: Analyzed 400 m running performance metric data from the fastest athlete with bilateral leg amputations
DOI: 10.6084/m9.figshare.17427586
title: Running Performance Metric Summary Data from Sprinting with prosthetic versus biological legs: insight from experimental data

description: Analyzed 400 m running performance metric data from the fastest athlete with bilateral leg amputations
DOI: 10.6084/m9.figshare.17427589
title: Metabolic Running Raw Data from Sprinting with prosthetic versus biological legs: insight from experimental data

description: Aerobic metabolism data from the fastest athlete with bilateral leg amputations during submax and maximum aerobic running trials
DOI: 10.6084/m9.figshare.17427595.v1
title: Starting Block Acceleration Raw Data from Sprinting with prosthetic versus biological legs: insight from experimental data

description: Radar gun and starting block ground reaction force data from the fastest athlete with bilateral leg amputations during 0–20 m sprint trials
DOI: 10.6084/m9.figshare.17427595
title: Starting Block Acceleration Raw Data from Sprinting with prosthetic versus biological legs: insight from experimental data

description: Radar gun and starting block ground reaction force data from the fastest athlete with bilateral leg amputations during 0–20 m sprint trials
DOI: 10.48370/ofd/ni9yvk/yrkmhg
title: HMW_Vicia_grandiflora_Scop._H_7217.jpg

description: :unav
DOI: 10.48370/ofd/ni9yvk
title: Wyka brudnożółta (Vicia grandiflora Scop.), 7217

description: Herbarium
DOI: 10.6084/m9.figshare.17427601
title: Data for revised Figure 2 from Outbreak of SARS-CoV-2 at a hospice—terminated after the implementation of enhanced aerosol infection control measures

description: Data for revised Figure 2
DOI: 10.25345/c51p3v
title: MassIVE MSV000088606 - GNPS - Combining HPLC Activity Profiling with Advanced UPLC-HRMS/MS Annotation to Accelerate the Discovery of Bioactive Natural Products
title: Dataset containing multiple Hyptis and Artemisia spp. used for the discovery of natural products inhibiting aberrant signaling, namely MAPK/ERK and PI3K/AKT, in melanoma
DOI: 10.6084/m9.figshare.17427605
title: Supplementary Material for: Benzodiazepine Use and Morbidity-Mortality Outcomes in a Geriatric Palliative Care Unit: A Retrospective Review

description: <b><i>Introduction:</i></b> Patients often experience delirium at the end of life. Benzodiazepine use may be associated with an increased risk of developing delirium. Alternate medications used in conjunction with benzodiazepines may serve as an independent precipitant of delirium. The aim is to understand the role of benzodiazepines in precipitating delirium and advanced mortality in palliative care population at the end of life. <b><i>Methods:</i></b> A retrospective medical chart review was conducted at a hospice and palliative care inpatient unit between the periods of June 2017–December 2017 and October 2017–November 2018. It included patients in hospice and palliative care inpatient units who received a benzodiazepine and those who did not. Patient characteristics, as well as Palliative Performance Scale score, diagnosis, and occurrence of admission, terminal, and/or recurrent delirium, were collected and analyzed. <b><i>Results:</i></b> Use of a benzodiazepine was not significantly associated with overall mortality nor cause-specific death without terminal delirium rate. However, it was significantly associated with higher cause-specific death with terminal delirium rate and a higher recurrent delirium rate. <b><i>Discussion:</i></b> This retrospective chart review suggests an association between benzodiazepine use and specific states of delirium and cause-specific death. However, it does not provide strong evidence on the use of this drug, especially at the end of life, as it pertains to the overall mortality rate. Suggested is a contextual approach to the use of benzodiazepines and the need to consider Palliative Performance Scale score and goals of care in the administration of this drug at varying periods during patient length of stay.
DOI: 10.6084/m9.figshare.17427605.v1
title: Supplementary Material for: Benzodiazepine Use and Morbidity-Mortality Outcomes in a Geriatric Palliative Care Unit: A Retrospective Review

description: <b><i>Introduction:</i></b> Patients often experience delirium at the end of life. Benzodiazepine use may be associated with an increased risk of developing delirium. Alternate medications used in conjunction with benzodiazepines may serve as an independent precipitant of delirium. The aim is to understand the role of benzodiazepines in precipitating delirium and advanced mortality in palliative care population at the end of life. <b><i>Methods:</i></b> A retrospective medical chart review was conducted at a hospice and palliative care inpatient unit between the periods of June 2017–December 2017 and October 2017–November 2018. It included patients in hospice and palliative care inpatient units who received a benzodiazepine and those who did not. Patient characteristics, as well as Palliative Performance Scale score, diagnosis, and occurrence of admission, terminal, and/or recurrent delirium, were collected and analyzed. <b><i>Results:</i></b> Use of a benzodiazepine was not significantly associated with overall mortality nor cause-specific death without terminal delirium rate. However, it was significantly associated with higher cause-specific death with terminal delirium rate and a higher recurrent delirium rate. <b><i>Discussion:</i></b> This retrospective chart review suggests an association between benzodiazepine use and specific states of delirium and cause-specific death. However, it does not provide strong evidence on the use of this drug, especially at the end of life, as it pertains to the overall mortality rate. Suggested is a contextual approach to the use of benzodiazepines and the need to consider Palliative Performance Scale score and goals of care in the administration of this drug at varying periods during patient length of stay.
DOI: 10.25345/c5x58n
title: MassIVE MSV000088607 - HDXMS of ERK2-RSK2 and ERK2-RSK2-ORF45 complexes
title: Hydrogen deuterium exchange mass spectrometry data of the ERK2-RSK2 and ERK2-RSK2-ORF45 complexes. The noncatalytic viral protein ORF45 reconfigures ERK-RSK signaling in cells. This dataset identifies the ORF45-RSK2 interface.
DOI: 10.6084/m9.figshare.17427620
title: Untitled Item

description: Raw data sharing for PeerJ 67571: Cardiac morphology changes of horses as a response to training for various types of sports
DOI: 10.48366/r160189
title: N2O gas emission assessment of the ocean basins

description: This comparative analysis compares the N2O gas emissions during different sampling periods in the various ocean basins.
DOI: 10.34740/kaggle/dsv/2960409
title: AutoXGB
DOI: 10.6084/m9.figshare.17427680
title: Viscometric results from Antibacterial properties of poly (<i>N</i>,<i>N</i>-dimethylaminoethyl methacrylate) obtained at different initiator concentrations in solution polymerization

description: The samples of poly(<i>N</i>,<i>N</i>-dimethylaminoethyl methacrylate) were synthesized by radical polymerization. The amount of monomer and solvent was constant opposite to an amount of initiator which was changing. No clear relationship between polymerization conditions and the molecular weight of the polymer was found, probably due to the branched configuration of produced polymer. Bactericidal interactions in all samples against Gram-positive and Gram-negative bacteria have been demonstrated. However, the observed effect has various intensities, depending on the type of bacteria and the type of sample.
DOI: 10.6084/m9.figshare.17427680.v1
title: Viscometric results from Antibacterial properties of poly (<i>N</i>,<i>N</i>-dimethylaminoethyl methacrylate) obtained at different initiator concentrations in solution polymerization

description: The samples of poly(<i>N</i>,<i>N</i>-dimethylaminoethyl methacrylate) were synthesized by radical polymerization. The amount of monomer and solvent was constant opposite to an amount of initiator which was changing. No clear relationship between polymerization conditions and the molecular weight of the polymer was found, probably due to the branched configuration of produced polymer. Bactericidal interactions in all samples against Gram-positive and Gram-negative bacteria have been demonstrated. However, the observed effect has various intensities, depending on the type of bacteria and the type of sample.
DOI: 10.6084/m9.figshare.17427683
title: Molecular weight calculation from Antibacterial properties of poly (<i>N</i>,<i>N</i>-dimethylaminoethyl methacrylate) obtained at different initiator concentrations in solution polymerization

description: The samples of poly(<i>N</i>,<i>N</i>-dimethylaminoethyl methacrylate) were synthesized by radical polymerization. The amount of monomer and solvent was constant opposite to an amount of initiator which was changing. No clear relationship between polymerization conditions and the molecular weight of the polymer was found, probably due to the branched configuration of produced polymer. Bactericidal interactions in all samples against Gram-positive and Gram-negative bacteria have been demonstrated. However, the observed effect has various intensities, depending on the type of bacteria and the type of sample.
DOI: 10.6084/m9.figshare.17427683.v1
title: Molecular weight calculation from Antibacterial properties of poly (<i>N</i>,<i>N</i>-dimethylaminoethyl methacrylate) obtained at different initiator concentrations in solution polymerization

description: The samples of poly(<i>N</i>,<i>N</i>-dimethylaminoethyl methacrylate) were synthesized by radical polymerization. The amount of monomer and solvent was constant opposite to an amount of initiator which was changing. No clear relationship between polymerization conditions and the molecular weight of the polymer was found, probably due to the branched configuration of produced polymer. Bactericidal interactions in all samples against Gram-positive and Gram-negative bacteria have been demonstrated. However, the observed effect has various intensities, depending on the type of bacteria and the type of sample.
DOI: 10.48366/r160205
title: N2O gas emission assessment of the various oceanic regimes

description: This comparative analysis compares the N2O gas emissions during different sampling periods in the various oceanic regimes.
DOI: 10.48370/ofd/guuay3/nowsni
title: HMW_Vinca_minor_L._H_8771.jpg

description: :unav
DOI: 10.48370/ofd/guuay3
title: Barwinek pospolity (Vinca minor L.), 8771

description: Herbarium
DOI: 10.48370/ofd/jkfprd/wbhms1
title: HMW_Vinca_minor_L._H_7538.jpg

description: :unav
DOI: 10.48370/ofd/jkfprd
title: Barwinek pospolity (Vinca minor L.), 7538

description: Herbarium
DOI: 10.48370/ofd/f1m9ip/vfbrcl
title: HMW_Vinca_minor_L._H_7230.jpg

description: :unav
DOI: 10.48370/ofd/f1m9ip
title: Barwinek pospolity (Vinca minor L.), 7230

description: Herbarium
DOI: 10.48370/ofd/4ot1hb/xvvwty
title: HMW_Vinca_minor_L._H_4896.jpg

description: :unav